Anna Karmann is a highly experienced leader in the medical and biopharmaceutical fields, currently serving as the Chief Medical Officer at AdvanCell since 2024, where responsibilities include overseeing global clinical development and regulatory strategies. Prior to this role, Karmann held the position of Vice President and Global Product Leader at RayzeBio, contributing to significant FDA submissions and managing strategic partnerships, while also playing a key role in the company's successful IPO and acquisition by Bristol Myers Squibb. Karmann's background includes an impactful tenure at McKinsey & Company as an Engagement Manager, a physician scientist position at Stanford University, and extensive experience in radiology and clinical trials, complemented by an extensive educational foundation with multiple advanced degrees, including a PhD from Maastricht University and an Executive MBA from Tsinghua University and RWTH Aachen University.
This person is not in any teams
This person is not in any offices